Takeda and Pfizer declare positive Phase III HD21 trial of ADCETRIS

Takeda and Pfizer have jointly announced positive outcomes from the Phase III HD21 trial, assessing ADCETRIS (brentuximab vedotin) combined with chemotherapy.

The trial revealed superior progression-free survival (PFS) and enhanced tolerability among patients newly diagnosed with Hodgkin lymphoma.

Conducted by the German Hodgkin Study Group (GHSG) and backed by Takeda, the four-year HD21 study is a Phase III, randomized, multi-country, open-label trial.

It juxtaposed ADCETRIS with BrECADD chemotherapy against the standard eBEACOPP regimen in individuals with Stage IIb/III/IV classical Hodgkin lymphoma.

At the preplanned three-year analysis, the study achieved its co-primary endpoints, indicating significantly improved safety and non-inferior PFS with the ADCETRIS combination.

HD21's co-primary endpoints encompass treatment-related morbidity and progression-free survival, complemented by secondary endpoints evaluating overall survival and quality of life, among other factors.